The FDA on Wednesday accepted Karuna Therapeutics’ New Drug Application for its investigational schizophrenia treatment KarXT (xanomeline-trospium), with a target action date of Sept. 26, 2024.30 Νοε 2023 is this true news?
3 Likes
This topic was automatically closed 14 days after the last reply. New replies are no longer allowed.